Updated on 2025/06/10

写真a

 
KOSHI Eri
 
Organization
Research Center of Health, Physical Fitness and Sports Division of Health Science Assistant Professor
Graduate School
Graduate School of Medicine
Undergraduate School
School of Medicine Department of Medicine
Title
Assistant Professor
External link

Degree 1

  1. MD （ 2013.3   Nagoya University ） 

To the head of Degree.▲

Research Interests 5

  1. nephrotic syndrome

  2. nephrology

  3. peripheral blood monocyte cells

  4. multi-omics analysis

  5. IgA nephritis

To the head of Research Interests.▲

Research Areas 2

  1. Life Science / Genome biology

  2. Life Science / Nephrology

To the head of Research Areas.▲

Current Research Project and SDGs 1

  1. 難治性腎疾患の治療最適化

To the head of Current Research Project and SDGs.▲

Research History 4

  1. Nagoya University   Research Center of Health, Physical Fitness and Sports Division of Health Science   Assistant Professor

    2025.6

  2. Nagoya University   Graduate School of Medicine Center for Research of Laboratory Animals and Medical Research Engineering Division for Advanced Medical Research   Assistant Professor

    2024.2 - 2025.5

  3. Nagoya University   Graduate School of Medicine

    2021.4

  4. Fujita Health University   Assistant Professor

    2017.4 - 2019.3

To the head of Research History.▲

Education 2

  1. Nagoya University

    2019.4 - 2024.1

  2. Nagoya University

    2007.4 - 2013.3

To the head of Education.▲

Professional Memberships 4

  1. 日本腎臓学会   腎臓指導医、腎臓専門医、SRチーム

  2. 日本遺伝カウンセリング学会   専攻医

  3. 日本透析医学会   透析専門医

  4. 日本内科学会   総合内科専門医、認定内科医、JMECCインストラクター

To the head of Professional Memberships.▲

Committee Memberships 2

  1. 日本腎臓学会   「腎障害患者におけるヨード造影剤使用に関するガイドライン改訂委員会」 委員  

    2025.2   

    　 More details

    Committee type：Academic society

  2. 日本腎臓学会   学術委員会SRチーム  

    2018.4   

    　 More details

    Committee type：Academic society

    腎障害患者におけるヨード造影剤使用に関するガイドライン2018
    PKDガイドライン2020
    CKDガイドライン2023
    PKDガイドライン2026

To the head of Committee Memberships.▲

Awards 5

  1. 日本女性腎臓病医の会（JSWN）研究活動奨励賞

    2023.6   日本女性腎臓病医の会   微小変化型ネフローゼに対するリツキシマブ治療の作用機構の全容解明を目指して－ヒト末梢血白血球の網羅的解析を通して

    　More details

    Award type：Award from Japanese society, conference, symposium, etc. 

  2. 奨励賞

    2018.1   藤田医科大学医学部腎内科学同門会  

  3. 第8回腎不全研究会特別奨励賞

    2017.12   腎不全研究会  

  4. 第19回名古屋大学医学部つるま賞

    2013.3   名古屋大学  

  5. 日本内科学会第218回東海地方会優秀演題賞

    2012.10   日本内科学会   原発性膜性腎症の治療反応性に寄与する因子の検討

    　More details

    Award type：Award from Japanese society, conference, symposium, etc. 

To the head of Awards.▲
 

Papers 23

  1. Urinary presepsin can efficiently detect T-cell-mediated rejection in patients who have undergone kidney transplantation Invited Reviewed Open Access

    Clin Exp Nephrol.     2025.4

    　More details

  2. Urinary presepsin is a novel biomarker capable of directly assessing monocyte/macrophage infiltration in kidney diseases. Reviewed

    Niwa S, Tanaka A, Furuhashi K, Hattori K, Onogi C, Sunohara K, Owaki A, Kato A, Kawazoe T, Watanabe Y, Koshi-Ito E, Kato N, Kosugi T, Maruyama S.

    Scientific Reports   Vol. 14 ( 1 ) page： 30088   2024.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  3. Association between alpha blocker use and the risk of fractures in patients with chronic kidney disease: a cohort study. Reviewed

    Sunohara K, Onogi C, Tanaka A, Furuhashi K, Matsumoto J, Hattori K, Owaki A, Kato A, Kawazoe T, Watanabe Y, Koshi-Ito E, Maruyama S

    BMC Nephrology   Vol. 25 ( 1 ) page： 442   2024.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  4. Prognosis of microscopic polyangiitis is well predictable in the first 2 weeks of treatment Reviewed

    Owaki A; Tanaka A; Kazuhiro Furuhashi; Watanabe Y; Koshi-Ito E; Imaizumi T; Maruyama S

    Clinical and experimental nephrology   Vol. 28 ( 7 ) page： 701 - 706   2024.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10157-024-02522-6

  5. Associations of time-dependent changes in phosphorus levels with cardiovascular diseases in patients undergoing hemodialysis: results from the Japan Dialysis Active Vitamin D (J-DAVID) randomized clinical trial. Reviewed

    Koshi-Ito E, Inaguma D, Ishii H, Yuzawa Y, Kabata D, Shintani A, Inaba M, Emoto M, Mori K, Morioka T, Nakatani S, Shoji T

    Clinical kidney journal   Vol. 15 ( 12 ) page： 2281 - 2291   2022.12

    　More details

    Authorship：Lead author   Language：English  

    DOI： 10.1093/ckj/sfac172

    PubMed

  6. Systematic characterization of seed overlap microRNA cotargeting associated with lupus pathogenesis. Reviewed Open Access

    Kitai H, Kato N, Ogami K, Komatsu S, Watanabe Y, Yoshino S, Koshi E, Tsubota S, Funahashi Y, Maeda T, Furuhashi K, Ishimoto T, Kosugi T, Maruyama S, Kadomatsu K, Suzuki HI

    BMC biology   Vol. 20 ( 1 ) page： 248   2022.11

    　More details

    Language：English   Publisher：BMC Biology  

    Background: Combinatorial gene regulation by multiple microRNAs (miRNAs) is widespread and closely spaced target sites often act cooperatively to achieve stronger repression (“neighborhood” miRNA cotargeting). While miRNA cotarget sites are suggested to be more conserved and implicated in developmental control, the pathological significance of miRNA cotargeting remains elusive. Results: Here, we report the pathogenic impacts of combinatorial miRNA regulation on inflammation in systemic lupus erythematosus (SLE). In the SLE mouse model, we identified the downregulation of two miRNAs, miR-128 and miR-148a, by TLR7 stimulation in plasmacytoid dendritic cells. Functional analyses using human cell lines demonstrated that miR-128 and miR-148a additively target KLF4 via extensively overlapping target sites (“seed overlap” miRNA cotargeting) and suppress the inflammatory responses. At the transcriptome level, “seed overlap” miRNA cotargeting increases susceptibility to downregulation by two miRNAs, consistent with additive but not cooperative recruitment of two miRNAs. Systematic characterization further revealed that extensive “seed overlap” is a prevalent feature among broadly conserved miRNAs. Highly conserved target sites of broadly conserved miRNAs are largely divided into two classes—those conserved among eutherian mammals and from human to Coelacanth, and the latter, including KLF4-cotargeting sites, has a stronger association with both “seed overlap” and “neighborhood” miRNA cotargeting. Furthermore, a deeply conserved miRNA target class has a higher probability of haplo-insufficient genes. Conclusions: Our study collectively suggests the complexity of distinct modes of miRNA cotargeting and the importance of their perturbations in human diseases.

    DOI： 10.1186/s12915-022-01447-4

    Open Access

    Web of Science

    Scopus

    PubMed

  7. A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020. Reviewed

    Nishio S, Tsuchiya K, Nakatani S, Muto S, Mochizuki T, Kawano H, Hanaoka K, Hidaka S, Ichikawa D, Ishikawa E, Uchiyama K, Koshi-Ito E, Hayashi H, Makabe S, Ogata S, Mitobe M, Sekine A, Suwabe T, Kataoka H, Kai H, Kaneko Y, Kurashige M, Seta K, Shimazu K, Hama T, Miura K, Nakanishi K, Horie S, Furuichi K, Okada H, Narita I, Committee of Clinical Practical Guideline for Polycystic Kidney Disease 2020

    Clinical and experimental nephrology   Vol. 25 ( 12 ) page： 1292 - 1302   2021.12

    　More details

    Language：English  

    DOI： 10.1007/s10157-021-02097-6

    PubMed

  8. Relationship between selection of dosage forms of vitamin D receptor activators and short-term survival of patients on hemodialysis. Reviewed

    Koshi-Ito E, Inaguma D, Koide S, Takahashi K, Hayashi H, Tsuboi N, Hasegawa M, Maruyama S, Yuzawa Y

    Renal failure   Vol. 43 ( 1 ) page： 1528 - 1538   2021.12

    　More details

    Authorship：Lead author   Language：English  

    DOI： 10.1080/0886022X.2021.1995423

    PubMed

  9. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. Reviewed Open Access

    Koshi E, Saito S, Okazaki M, Toyama Y, Ishimoto T, Kosugi T, Hiraiwa H, Jingushi N, Yamamoto T, Ozaki M, Goto Y, Numaguchi A, Miyagawa Y, Kato I, Tetsuka N, Yagi T, Maruyama S

    CEN case reports   Vol. 10 ( 1 ) page： 126 - 131   2021.2

    　More details

    Language：English   Publisher：Cen Case Reports  

    BACKGROUND: Novel coronavirus disease 2019 (COVID-19) refers to infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen, and has spread to pandemic levels since its inception in December 2019. While several risk factors for severe presentation have been identified, the clinical course for end-stage renal disease (ESRD) patients on maintenance hemodialysis with COVID-19 has been unclear. Previous studies have revealed that some antiviral agents may be effective against COVID-19 in the general population, but the pharmacokinetics and pharmacodynamics of these agents in ESRD patients remain under investigation. Favipiravir, an antiviral agent developed for treatment of influenza, is one candidate treatment for COVID-19, but suitable dosages for patients with renal insufficiency are unknown. Here we provide a first report on the efficacy of favipiravir in a patient with ESRD undergoing hemodialysis. CASE PRESENTATION: The case involved a 52-year-old woman with COVID-19 who had been undergoing maintenance hemodialysis three times a week for 3 years due to diabetic nephropathy. She had initially been treated with lopinavir/ritonavir and ciclesonide for 5 days, but developed severe pneumonia requiring invasive positive-pressure ventilation. Those antiviral agents were subsequently switched to favipiravir. She recovered gradually, and after 2 weeks was extubated once the viral load of SARS-CoV-2 fell below the limit of detection. Although concentrations of several biliary enzymes were elevated, no major adverse events were observed. CONCLUSION: Favipiravir may be an effective option for the treatment of COVID-19-infected patients with ESRD.

    DOI： 10.1007/s13730-020-00534-1

    Open Access

    Web of Science

    Scopus

    PubMed

  10. Extreme hyperuricemia is a risk factor for infection-related deaths in incident dialysis patients: a multicenter prospective cohort study. Open Access

    Yoshida H, Inaguma D, Koshi-Ito E, Ogata S, Kitagawa A, Takahashi K, Koide S, Hayashi H, Hasegawa M, Yuzawa Y, Tsuboi N

    Renal failure   Vol. 42 ( 1 ) page： 646 - 655   2020.11

    　More details

    Language：English   Publisher：Informa UK Limited  

    There are few studies on the association between serum uric acid (UA) level and mortality in incident dialysis patients. We aimed to clarify whether the serum UA level at dialysis initiation is associated with mortality during maintenance dialysis.We enrolled 1486 incident dialysis patients who participated in a previous multicenter prospective cohort study in Japan. We classified the patients into the following five groups according to their serum UA levels at dialysis initiation: G1 with a serum UA level6 mg/dL; G2, 6.0-8.0 mg/dL; G3, 8.0-10.0 mg/dL; G4, 10.0-12.0 mg/dL; and G5, ≥12.0 mg/dL. We created three models (Model 1: adjusted for age and sex, Model 2: adjusted for Model 1 + 12 variables, and Model 3: stepwise regression adjusted for Model 2 + 13 variables) and performed a multivariate Cox proportional hazard regression analysis to examine the association between the serum UA level and outcomes, including infection-related mortality.Hazard ratios (HRs) were calculated relative to the G2, because the all-cause mortality rate was the lowest in G2. For Models 1 and 2, the all-cause mortality rate was significantly higher in G5 than in G2 (HR: 1.63, 95% confidence interval [CI]: 1.14-2.33 and HR: 1.78, 95% CI: 1.19-2.68, respectively). For Models 1, 2, and 3, the infection-related mortality rate was significantly higher in G5 than in G2 (HR: 2.75, 95% CI: 1.37-5.54, HR: 3.09, 95% CI: 1.45-6.59, HR: 3.37, and 95% CI: 1.24-9.15, respectively).Extreme hyperuricemia (serum UA level ≥12.0 mg/dL) at dialysis initiation is a risk factor for infection-related deaths.

    DOI： 10.1080/0886022X.2020.1788582

    Open Access

    PubMed

    CiNii Research

  11. Guideline on the use of iodinated contrast media in patients with kidney disease 2018. Reviewed Open Access

    Isaka Y, Hayashi H, Aonuma K, Horio M, Terada Y, Doi K, Fujigaki Y, Yasuda H, Sato T, Fujikura T, Kuwatsuru R, Toei H, Murakami R, Saito Y, Hirayama A, Murohara T, Sato A, Ishii H, Takayama T, Watanabe M, Awai K, Oda S, Murakami T, Yagyu Y, Joki N, Komatsu Y, Miyauchi T, Ito Y, Miyazawa R, Kanno Y, Ogawa T, Hayashi H, Koshi E, Kosugi T, Yasuda Y, Japanese Society of Nephrology, Japan Radiological Society, and Japanese Circulation Society Joint Working Group

    Clinical and experimental nephrology   Vol. 24 ( 1 ) page： 1 - 44   2020.1

    　More details

    Language：English   Publisher：Clinical and Experimental Nephrology  

    DOI： 10.1007/s10157-019-01750-5

    Open Access

    Web of Science

    Scopus

    PubMed

  12. Guideline on the use of iodinated contrast media in patients with kidney disease 2018. Reviewed Open Access

    Isaka Y, Hayashi H, Aonuma K, Horio M, Terada Y, Doi K, Fujigaki Y, Yasuda H, Sato T, Fujikura T, Kuwatsuru R, Toei H, Murakami R, Saito Y, Hirayama A, Murohara T, Sato A, Ishii H, Takayama T, Watanabe M, Awai K, Oda S, Murakami T, Yagyu Y, Joki N, Komatsu Y, Miyauchi T, Ito Y, Miyazawa R, Kanno Y, Ogawa T, Hayashi H, Koshi E, Kosugi T, Yasuda Y, Japanese Society of Nephrology, Japan Radiological Society, and Japanese Circulation Society Joint Working Group

    Japanese journal of radiology   Vol. 38 ( 1 ) page： 3 - 46   2020.1

    　More details

    Language：English   Publisher：Japanese Journal of Radiology  

    DOI： 10.1007/s11604-019-00850-2

    Web of Science

    Scopus

    PubMed

  13. Effect of Low-Density Lipoprotein Apheresis for Nephrotic Idiopathic Membranous Nephropathy as Initial Induction Therapy.

    Koshi-Ito E, Koike K, Tanaka A, Watanabe Y, Kamegai N, Shimogushi H, Shinjo H, Otsuka Y, Inaguma D, Takeda A

    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy   Vol. 23 ( 6 ) page： 575 - 583   2019.12

    　More details

    Language：English   Publisher：Wiley  

    <jats:title>Abstract</jats:title><jats:p>Low‐density lipoprotein apheresis (LDL‐A) has been used for nephrotic syndrome (NS) caused by focal segmental glomerulosclerosis in Japan. Idiopathic membranous nephropathy (iMN) can also cause treatment‐resistant NS. Therefore, we investigated the effect of LDL‐A during initial induction for it. This retrospective, observational, and single‐center study enrolled consecutive iMN patients who received steroids from March 2000 to May 2015. We compared data between 11 patients treated with LDL‐A (LDL‐A group) and 27 patients without (non‐LDL‐A group) at baseline and 4 and 8 weeks later. Reduction rate of proteinuria and increase rate of serum albumin in LDL‐A group were significantly higher than the other after 4 weeks (<jats:italic>P</jats:italic> = 0.036 and 0.030) and 8 weeks (<jats:italic>P</jats:italic> = 0.030 and <0.001), respectively. There was no adverse event caused by LDL‐A and immunosuppressant dose was not significantly different. In conclusion, LDL‐A may be an effective choice for initial induction of nephrotic iMN.</jats:p>

    DOI： 10.1111/1744-9987.12811

    PubMed

    CiNii Research

  14. Guideline on the Use of Iodinated Contrast Media in Patients With Kidney Disease 2018 Open Access

    Isaka Yoshitaka, Hayashi Hiromitsu, Aonuma Kazutaka, Horio Masaru, Terada Yoshio, Doi Kent, Fujigaki Yoshihide, Yasuda Hideo, Sato Taichi, Fujikura Tomoyuki, Kuwatsuru Ryohei, Toei Hiroshi, Murakami Ryusuke, Saito Yoshihiko, Hirayama Atsushi, Murohara Toyoaki, Sato Akira, Ishii Hideki, Takayama Tadateru, Watanabe Makoto, Awai Kazuo, Oda Seitaro, Murakami Takamichi, Yagyu Yukinobu, Joki Nobuhiko, Komatsu Yasuhiro, Miyauchi Takamasa, Ito Yugo, Miyazawa Ryo, Kanno Yoshihiko, Ogawa Tomonari, Hayashi Hiroki, Koshi Eri, Kosugi Tomoki, Yasuda Yoshinari, Japanese Society of Nephrology, Japan Radiological Society, the Japanese Circulation Society Joint Working Group

    Circulation Journal   Vol. 83 ( 12 ) page： 2572 - 2607   2019.11

    　More details

    Language：English   Publisher：The Japanese Circulation Society  

    DOI： 10.1253/circj.CJ-19-0783

    Open Access

    Web of Science

    Scopus

    PubMed

    CiNii Research

  15. Relationship Between Patterns in Antihypertensive Drugs Medication and Mortality in Incident Dialysis Patients: A Multicenter Prospective Cohort Study. Reviewed

    Fujii M, Inaguma D, Koide S, Ito E, Takahashi K, Hayashi H, Tsuboi N, Hasegawa M, Yuzawa Y

    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy   Vol. 23 ( 4 ) page： 353 - 361   2019.8

    　More details

    Language：English  

    DOI： 10.1111/1744-9987.12778

    PubMed

  16. Relationship between History of Ischemic Stroke and All-Cause Mortality in Incident Dialysis Patients. Reviewed

    Kojima M, Inaguma D, Koide S, Koshi-Ito E, Takahashi K, Hayashi H, Tsuboi N, Hasegawa M, Yuzawa Y

    Nephron   Vol. 143 ( 1 ) page： 43 - 53   2019

    　More details

    Language：English  

    DOI： 10.1159/000500485

    PubMed

  17. Prediction model for cardiovascular events or all-cause mortality in incident dialysis patients. Reviewed

    Inaguma D, Morii D, Kabata D, Yoshida H, Tanaka A, Koshi-Ito E, Takahashi K, Hayashi H, Koide S, Tsuboi N, Hasegawa M, Shintani A, Yuzawa Y

    PloS one   Vol. 14 ( 8 ) page： e0221352   2019

    　More details

    Language：English  

    DOI： 10.1371/journal.pone.0221352

    PubMed

  18. Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method. Reviewed

    Ito E, Inaguma D, Koide S, Takahashi K, Hayashi H, Hasegawa M, Yuzawa Y

    Clinical and experimental nephrology   Vol. 22 ( 6 ) page： 1309 - 1314   2018.12

    　More details

    Authorship：Lead author   Language：English  

    DOI： 10.1007/s10157-018-1584-0

    PubMed

  19. Impact of high mortality in incident dialysis patients due to hypertensive nephrosclerosis: a multicenter prospective cohort study in Aichi, Japan. Reviewed

    Inaguma D, Ito E, Takahashi K, Hayashi H, Koide S, Hasegawa M, Yuzawa Y, AICOPP Group

    Clinical and experimental nephrology   Vol. 22 ( 6 ) page： 1360 - 1370   2018.12

    　More details

    Language：English  

    DOI： 10.1007/s10157-018-1592-0

    PubMed

  20. Serum phosphate level at initiation of dialysis is associated with all-cause mortality: a multicenter prospective cohort study. Reviewed

    Owaki A, Inaguma D, Aoyama I, Inaba S, Koide S, Ito E, Takahashi K, Hayashi H, Hasegawa M, Yuzawa Y, AICOPP group

    Renal failure   Vol. 40 ( 1 ) page： 475 - 482   2018.11

    　More details

    Language：English  

    DOI： 10.1080/0886022X.2018.1499530

    PubMed

  21. Aortic stenosis is a risk factor for all-cause mortality in patients on dialysis: a multicenter prospective cohort analysis. Reviewed

    Inaguma D, Sasakawa Y, Suzuki N, Ito E, Takahashi K, Hayashi H, Koide S, Hasegawa M, Yuzawa Y, Tokai Aortic Stenosis in Dialysis Patients Cohort Study Group

    BMC nephrology   Vol. 19 ( 1 ) page： 80   2018.4

    　More details

    Language：English  

    DOI： 10.1186/s12882-018-0877-6

    PubMed

  22. Ratio of blood urea nitrogen to serum creatinine at initiation of dialysis is associated with mortality: a multicenter prospective cohort study. Reviewed

    Inaguma D, Koide S, Ito E, Takahashi K, Hayashi H, Hasegawa M, Yuzawa Y, AICOPP group

    Clinical and experimental nephrology   Vol. 22 ( 2 ) page： 353 - 364   2018.4

    　More details

    Language：English  

    DOI： 10.1007/s10157-017-1458-x

    PubMed

  23. Combination Therapy with Renin-Angiotensin System Blockers and Vitamin D Receptor Activators for Predialysis Patients Is Associated with the Incidence of Cardiovascular Events after Dialysis Initiation: A Multicenter Nonrandomized Prospective Cohort Study. Reviewed

    Inaguma D, Ito E, Koide S, Takahashi K, Hayashi H, Hasegawa M, Yuzawa Y

    Cardiorenal medicine   Vol. 8 ( 1 ) page： 71 - 81   2017.12

    　More details

    Language：English  

    DOI： 10.1159/000479894

    PubMed

▼display all

To the head of Papers.▲

Books 5

  1. エビデンスに基づくCKD診療ガイドライン 2023 Reviewed

    （ Role： Contributor ,  11-9 CKD患者のシックデイにおける薬物の中止[丸山彰一, 小杉智規, 安田宜成, 西堀暢浩, 鈴木克彦, 武田有記, 古志衣里]）

    東京医学社  2023.6  （ ISBN:9784885637414 ）

  2. エビデンスに基づく多発性囊胞腎（PKD）診療ガイドライン2020 Reviewed

    （ Role： Contributor ,  CQ2.ADPKDの治療にトルバプタンは推奨されるか？[林宏樹, 古志衣里, 尾形宗士郎]）

    東京医学社  2020.8  （ ISBN:9784885637247 ）

    　More details

    Language：Japanese Book type：Scholarly book

  3. 腎障害患者におけるヨード造影剤使用に関するガイドライン2018 Reviewed

    （ Role： Contributor）

    東京医学社  2018.10  （ ISBN:9784885632952 ）

    　More details

    Language：Japanese Book type：Scholarly book

  4. 内科学書改訂第9版vol.3

    南学正臣（ Role： Contributor ,  7．尿細管間質性腎炎［湯澤由紀夫，稲熊大城，古志衣里］）

    中山書店  2019.8  （ ISBN:978-4-521-74749-1 ）

    　More details

    Language：Japanese

  5. 糖尿病性腎臓病の診かた,考えかた

    和田隆志　 編著 ／ 柏原直樹　 編著（ Role： Contributor ,  Ch. III 診断・バイオマーカー）

    中外医学社  2018.6  （ ISBN:978-4-498-22436-0 ）

    　More details

    Total pages：224   Language：Japanese Book type：Scholarly book

To the head of Books.▲

Presentations 4

  1. 微小変化型ネフローゼに対するリツキシマブ治療の作用機構の全容解明を目指して―ヒト末梢血白血球の網羅的解析を通して― Invited

    古志衣里

    日本女性腎臓病医の会第21回総会  2024.6.8  日本女性腎臓病医の会

    　More details

    Event date： 2024.6

    Language：Japanese  

    Venue：横浜市  

  2. 微小変化型ネフローゼに対するリツキシマブ治療の作用機構の全容解明を目指して―ヒト末梢血白血球の網羅的解析を通して― Invited

    古志衣里

    日本女性腎臓病医の会第20回総会（受賞講演）  2023.6.9 

    　More details

    Event date： 2023.6

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

  3. Early introduction of intravenous VDRA could be associated with better prognosis of end-stage kidney disease patients on hemodialysis International conference

    the 55th ERA-EDTA Congress in Copenhagen, Denmark  2018.5.15 

    　More details

    Event date： 2018.5

    Language：English   Presentation type：Poster presentation  

    Country：Denmark  

  4. Efficacy of LDL apheresis for initial induction therapy of nephrotic membranous nephropathy International conference

    Eri Koshi

    the 54th ERA-EDTA Congress in Madrid, Spain  2017.6.4  ERA-EDTA

    　More details

    Event date： 2017.6

    Language：English   Presentation type：Poster presentation  

    Venue：Madrid   Country：Spain  

To the head of Presentations.▲

Other research activities 4

  1. J-MARINE2 study

    2025.3

  2. NNMAC

    2023.6

  3. Comprehensive analysis of changes in peripheral blood induced by HIF-PH inhibitors

    2023.9

  4. Comprehensive analysis of effects on peripheral blood cells induced by ADR-001 for IgA nephropathy

    2023.4

To the head of Other research activities.▲

Research Project for Joint Research, Competitive Funding, etc. 4

  1. 微小変化型ネフローゼに対するリツキシマブの治療機序解明

    Grant number：YRY-2412  2024.11

    2024年度横山臨床薬理研究助成基金 

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    Grant amount：\1000000

  2. ヒト末梢血白血球網羅的解析が解き明かす微小変化型ネフローゼ進行に関わる免疫学的機序

    2023.8 - 2024.3

    愛知腎臓財団研究助成費 

    　 More details

    Grant type：Competitive

    Grant amount：\200000

  3. 活性型ビタミンDと炭酸ランタンとの併用が血清FGF23濃度に与える影響に関する研究

    2018.4 - 2019.3

    愛知腎臓財団研究助成費 

    　 More details

    Grant type：Competitive

    Grant amount：\250000

  4. 活性型ビタミンDと炭酸ランタンとの併用が血清FGF23濃度に与える影響に関する研究

    2018.4 - 2019.3

    日本腎臓財団公募助成（腎不全病態研究助成） 

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    Grant amount：\600000

To the head of Research Project for Joint Research, Competitive Funding, etc..▲

KAKENHI (Grants-in-Aid for Scientific Research) 2

  1. Elucidation of the Immune Regulatory Mechanisms Involved in the Treatment and Responsiveness of IgA Nephropathy Using Multi-Omics Analysis

    Grant number：24K23431  2024.9

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    Grant amount：\2860000 （ Direct Cost: \2200000 、 Indirect Cost：\660000 ）

  2. 難治性の希少腎疾患に対する治療最適化に向けた研究開発

    Grant number：24ek0109753h0001  2024.4

    国立研究開発法人　日本医療研究開発機構  令和6年度「難治性疾患実用化研究事業」 

    　 More details

    Authorship：Coinvestigator(s)  Grant type：Competitive

    Grant amount：\97500000 （ Direct Cost: \75000000 、 Indirect Cost：\22500000 ）

To the head of KAKENHI (Grants-in-Aid for Scientific Research).▲
 

Teaching Experience (On-campus) 2

  1. 腎臓内科学

    2025

    　詳細を見る

    ポリクリ１

  2. 腎臓内科学

    2024

    　詳細を見る

    ポリクリ１レクチャーとして「腎臓病の分類」の講義を行っている

To the head of Teaching Experience (On-campus).▲